SEC Info - Pfizer Inc. - ‘8-K’ for 1/31/23

SEC Info℠

Home

Help

Please Sign In

Pfizer Inc. – ‘8-K’ for 1/31/23

On: Tuesday, 1/31/23, at 8:11am ET · For: 1/31/23 · Accession #: 78003-23-4 · File #: 1-03619

  As Of               Filer                 Filing    For·On·As Docs:Size

 1/31/23  Pfizer Inc.                       8-K:2,9     1/31/23   12:1.7M

Current Report — Form 8-K

Filing Table of Contents

Document/Exhibit                   Description                      Pages   Size 

 1: 8-K         Current Report                                      HTML     44K 
 2: EX-99       Miscellaneous Exhibit                               HTML   1.43M 
 7: R1          Cover Page                                          HTML     50K 
10: XML         IDEA XML File -- Filing Summary                      XML     12K 
 8: XML         XBRL Instance -- pfe-20230131_htm                    XML     28K 
 9: EXCEL       IDEA Workbook of Financial Reports                  XLSX      8K 
 4: EX-101.DEF  XBRL Definitions -- pfe-20230131_def                 XML     40K 
 5: EX-101.LAB  XBRL Labels -- pfe-20230131_lab                      XML     84K 
 6: EX-101.PRE  XBRL Presentations -- pfe-20230131_pre               XML     40K 
 3: EX-101.SCH  XBRL Schema -- pfe-20230131                          XSD     12K 
11: JSON        XBRL Instance as JSON Data -- MetaLinks               14±    20K 
12: ZIP         XBRL Zipped Folder -- 0000078003-23-000004-xbrl      Zip    115K

‘8-K’ — Current Report

This is an HTML Document rendered as filed. [ Alternative Formats ]

iX: C: C:

pfe-20230131

i 0000078003 i false00000780032023-01-312023-01-310000078003us-gaap:CommonStockMember2023-01-312023-01-310000078003pfe:NotesDue20271.000Member2023-01-312023-01-31

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM i i 8-K /

CURRENT REPORT

PURSUANT TO SECTION 13 OR 15(d) OF THE

SECURITIES EXCHANGE ACT OF 1934

Date of report (Date of earliest event reported): i January 31, 2023

i i PFIZER INC / .

(Exact name of registrant as specified in its charter)


i Delaware	i 1-3619	i 13-5315170
(State or other	(Commission File	(I.R.S. Employer
jurisdiction of	Number)	Identification No.)
incorporation)


i 235 East 42nd Street		i 10017
i New York,	i New York	(Zip Code)

(Address of principal executive offices)

Registrant’s telephone number, including area code:

( i 212) i 733-2323

(Former name or former address, if changed since last report)

Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the obligation of the registrant under any of the following provisions (see General Instruction A.2. below):

i ☐ Written communication pursuant to Rule 425 under the Securities Act (17 CFR 230.425)

i ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)

i ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2 (b))

i ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

Securities registered pursuant to Section 12(b) of the Act:

Title of each class

Trading Symbol(s)

Name of each exchange on which registered

i Common Stock, $.05 par value

i PFE

i New York Stock Exchange

i 1.000% Notes due 2027

i PFE27

i New York Stock Exchange

Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

Emerging growth company i ☐

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

Item 2.02 Results of Operations and Financial Condition

On January 31, 2023, Pfizer Inc. (“Pfizer”) issued a press release announcing its financial results for fourth-quarter and full-year 2022. A copy of the press release is furnished herewith as Exhibit 99 and is incorporated by reference herein.

The information furnished pursuant to this “Item 2.02 - Results of Operations and Financial Condition”, including Exhibit 99, shall not be deemed to be “filed” for the purposes of Section 18 of the Securities Exchange Act of 1934, as amended (“Exchange Act”) or otherwise subject to the liabilities of that section, and shall not be deemed to be incorporated by reference into any filing made by us under the Exchange Act or Securities Act of 1933, as amended, regardless of any general incorporation language in any such filing, except as shall be expressly set forth by specific reference in such filing.

Item 9.01 Financial Statements and Exhibits

(d) Exhibits


Exhibit Number						Exhibit Description

Exhibit 99						Press Release of Pfizer Inc. dated January 31, 2023, reporting Pfizer’s financial results for fourth-quarter and full-year 2022.
104						Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.


						EXHIBIT INDEX

Exhibit No.						Description

99						Press Release of Pfizer Inc. dated January 31, 2023, reporting Pfizer’s financial results for fourth-quarter and full-year 2022.
104						Cover Page Interactive Data File--the cover page XBRL tags are embedded within the Inline XBRL document.

SIGNATURE

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.


			PFIZER INC.


			By:			/s/ *Margaret M. Madden*
						Margaret M. Madden
						Senior Vice President and Corporate Secretary
						Chief Governance Counsel

Dated: January 31, 2023

Dates Referenced Herein and Documents Incorporated by Reference

This ‘8-K’ Filing	Date	Other Filings

Filed on / For Period end:	1/31/23	None on these Dates
		List all Filings

1 Subsequent Filing that References this Filing

  As Of               Filer                 Filing    For·On·As Docs:Size             Issuer                      Filing Agent

 2/27/23  Pfizer Inc.                       S-8         2/27/23    4:104K

↑Top

Filing Submission 0000078003-23-000004 – Alternative Formats (Word / Rich Text, HTML, Plain Text, et al.)